In recent years, the cell and gene therapy market has been touted as a promising frontier in the pharmaceutical industry. Numerous clinical trials and regulatory approvals have driven a wave of investment and innovation. However, some analyst commentary is starting to question whether the market's early momentum has begun to wane. Despite a pipeline of nearly 400 ongoing clinical trials in Europe alone, doubts remain about whether these products will make it to market and if the recent flurry of activity is sustainable.